We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Red Blood Cells Function as Critical Immune Sensors by Binding Cell-Free DNA

By LabMedica International staff writers
Posted on 04 Nov 2021
Print article
Image: Erythrophagocytosis by splenic macrophages (arrows):  DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia (Photo courtesy of Tekportal)
Image: Erythrophagocytosis by splenic macrophages (arrows): DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia (Photo courtesy of Tekportal)
Red blood cells (RBCs) are essential for aerobic respiration through delivery of oxygen to distant tissues. However, RBCs are currently considered immunologically inert, and few, if any, secondary functions of RBCs have been identified.

Although non–gas exchanging functions of the red cell such as chemokine regulation, complement binding, and pathogen immobilization have been described, RBC immune function remains enigmatic. RBCs transit through all tissues and contact pathogen and self-derived inflammatory mediators in the circulation, positioning them as ideal messengers between distant organs.

A large team of Clinical Scientists led by those at the University of Pennsylvania School of Medicine (Philadelphia, PA, USA) examined the red blood cells of about 50 sepsis patients and 100 COVID-19 patients and found that, during these illnesses, red blood cells express an increased amount of the specific Toll-like receptors (TLR) protein called TLR9 on their surface. TLRs are a class of proteins that play a key role in the immune system by activating immune responses like cytokine production. Hemoglobin parameters were collected from the electronic medical record complete blood count on days 0 and 7, selecting the lowest value from the day if more than one measurement was available per day.

The investigators showed that when the red blood cells bind too much inflammation-causing nucleic acid, they lose their normal structure, causing the body to not recognize them anymore. This leads to erythrophagocytosis by splenic macrophages, resulting in acute anemia. When this happens it causes the immune system to become activated in otherwise unaffected organs, creating inflammation. This mechanistic discovery opens the door to studies on how to block this specific receptor and create targeted therapies for autoimmune diseases, infectious diseases, and a whole host of inflammatory illnesses associated with acute anemia.

The detection and capture of nucleic acid by TLR9-expressing RBCs regulated red cell clearance and inflammatory cytokine production, demonstrating that RBCs function as immune sentinels during pathologic states. Consistent with these findings, RBC-bound mitochondrial DNA was elevated in individuals with viral pneumonia and sepsis secondary to coronavirus disease 2019 (COVID-19) and associated with anemia and severity of disease.

Nilam Mangalmurti, MD, an assistant professor and senior author of the study, said, “Anemia is common, affecting about a quarter of the world’s population. Acute inflammatory anemia is often seen early after an infection such as parasitic infections that cause malaria. For a long time we haven’t known why people, when they are critically ill from sepsis, trauma, COVID-19, a bacterial infection, or parasite infection, develop an acute anemia. These findings explain one of the mechanisms for the development of acute inflammatory anemia for the first time.”

The authors concluded that they had demonstrated that RBCs serve as DNA sensors through surface expression of TLR9, which appears to be beneficial during quiescent states, where it promotes scavenging of trace CpG to prevent nonspecific inflammation. However, during conditions characterized by excess circulating CpG, such as sepsis and COVID-19, binding of CpG by RBC-TLR9 leads to accelerated clearance and inflammation. The study was published on October 20, 2021 in the journal Science Translational Medicine.

Related Links:
University of Pennsylvania School of Medicine

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test
New
Gold Member
HIV Test
HIV Test - I541

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.